CredoScientia - Bibliothèque

Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.

BACKGROUND: Liver metastasis is one of the most common causes of death in patients with colorectal cancer. Therefore, improving the treatment effect of liver metastatic carcinoma of colorectal cancer …

Thérapies de Conversion

Peng, K., Li, Y., Su, H., Lan, C., Huang, Z., Wei, Y., Liao, X., Peng, M., Peng, T., & Zhu, G. (2023). Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.. Front Immunol, 14, 1325445. https://doi.org/10.3389/fimmu.2023.1325445

01/01/2023 Lire →

Medical students' perceptions of LGBTQ+ healthcare in Singapore and the United Kingdom.

INTRODUCTION: Lesbian, gay, bisexual, transgender, queer, and other sexual and gender minority (LGBTQ+) individuals have an increased scope of healthcare needs and face many barriers to accessing heal…

Thérapies de Conversion

Fu, M. X., Zou, T., Aiyappan, R., Ye, X., Onanuga, S., Tan, A., Smith, S., & Baptista, A. (2023). Medical students' perceptions of LGBTQ+ healthcare in Singapore and the United Kingdom.. Front Med (Lausanne), 10, 1236715. https://doi.org/10.3389/fmed.2023.1236715

01/01/2023 Lire →

Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report.

Hepatocellular carcinoma (HCC) recurrence, which encompasses both true recurrence resulting from cancer spread and de novo tumors developing within the same cancer-prone liver, presents a complication…

Thérapies de Conversion

Chen, J., Liao, X., Wu, Y., Ou, S., Qin, W., Yang, C., Tan, Y., Lao, Q., Peng, M., Peng, T., & Ye, X. (2023). Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report.. Pharmgenomics Pers Med, 16, 949-958. https://doi.org/10.2147/PGPM.S426791

01/01/2023 Lire →

Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.

BACKGROUND: Hepatocellular carcinoma (HCC) with a dismal prognosis is the second most deadly malignancy globally. Surgery is believed to be a curative approach. Nevertheless, there is still a consider…

Thérapies de Conversion

Wei, Y. G., Su, H., Lv, Z. L., Liao, X. W., Zeng, Z. M., Jia, Y. X., Huang, H. S., Shen, X. Q., Zhu, G. Z., Han, C. Y., Ye, X. P., & Peng, T. (2023). Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.. Front Oncol, 13, 1165538. https://doi.org/10.3389/fonc.2023.1165538

01/01/2023 Lire →

The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.

PURPOSE: To explore the safety and efficacy of lenvatinib in combination with trans-arterial chemoembolization (TACE) and programmed death receptor 1 (PD-1) antibody in the treatment of unresectable r…

Thérapies de Conversion

Mu, C., Shen, J., Zhu, X., Peng, W., Zhang, X., & Wen, T. (2023). The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.. Front Oncol, 13, 1096955. https://doi.org/10.3389/fonc.2023.1096955

01/01/2023 Lire →

Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two

Hepatocellular carcinoma (HCC) is often diagnosed at an unresectable stage without opportunities for curative therapy. Future liver remnant (FLR) insufficiency limits the range of patients who can und…

Thérapies de Conversion

Ning, C., Liu, G., Zhang, J., Yang, X., Xu, Y., & Zhao, H. (2023). Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two. Front Immunol, 14, 1159885. https://doi.org/10.3389/fimmu.2023.1159885

01/01/2023 Lire →

Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: A systematic review and meta-analysis.

The aim of this study was to systematically review the efficacy and tolerability of perampanel (PER) when used as add-on treatment or monotherapy in patients with epilepsy aged 12 years and older in …

Thérapies de Conversion

Hou, L., Yang, J., Zhang, X., Li, N., Li, S., Zhang, L., Zhao, J., & Wang, Q. (2023). Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: A systematic review and meta-analysis.. Front Pharmacol, 14, 1139514. https://doi.org/10.3389/fphar.2023.1139514

01/01/2023 Lire →

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.

PURPOSE: To evaluate the outcomes and prognostic factors for patients using conversion therapy with lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus programmed cell death …

Thérapies de Conversion

Li, X., Chen, J., Wang, X., Bai, T., Lu, S., Wei, T., Tang, Z., Huang, C., Zhang, B., Liu, B., Li, L., & Wu, F. (2023). Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.. Front Oncol, 13, 1110689. https://doi.org/10.3389/fonc.2023.1110689

01/01/2023 Lire →